Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH/MASH) — is the most common liver disease in the world, affecting approximately 25% of the global population. The approval of resmetirom (Rezdiffra) as the first FDA-cleared pharmacologic treatment for MASH with significant fibrosis has accelerated the build-out of digital health platforms designed to support diagnosis, risk stratification, treatment monitoring, and progression surveillance at scale. These platforms track FibroScan and MRI-PDFF results, manage metabolic risk factor trajectories, support resmetirom adherence monitoring and LDL surveillance, and coordinate non-invasive biomarker-based progression checks that replace serial liver biopsy for the majority of patients.
When NAFLD/NASH care platforms go down, clinicians lose access to the longitudinal imaging and biomarker data that defines a patient's current position on the fibrosis progression curve — information that is irreplaceable in real time and that directly drives treatment decisions.
This guide covers what NAFLD/NASH care technology platforms need to monitor, why continuous availability is essential for metabolic liver disease programs, and how to build a monitoring strategy that protects clinical quality, treatment adherence, and regulatory compliance.
Why NAFLD/NASH Care Tech Platforms Cannot Afford Downtime
NAFLD/NASH management is a longitudinal, data-intensive specialty. Fibrosis staging, metabolic risk factor trending, pharmacotherapy initiation, and progression surveillance all depend on accumulated imaging, laboratory, and clinical data that lives in the digital platform. Unlike acute conditions where each encounter is relatively self-contained, NAFLD/NASH care is defined by the trajectory — and the platform holds the trajectory record.
FibroScan and MRI-PDFF result access is foundational to staging and treatment decisions. Non-invasive fibrosis assessment through transient elastography (FibroScan liver stiffness measurement) and MRI-based fat quantification (MRI-PDFF) generates the data that defines whether a patient is a candidate for resmetirom therapy, whether they should be escalated to hepatology, or whether they can be managed with lifestyle intervention alone. When the platform cannot retrieve a patient's FibroScan or MRI-PDFF history during a clinic appointment, the clinician is making staging and treatment decisions without the data that those decisions depend on.
Resmetirom adherence and LDL monitoring requires continuous data access. Patients initiated on resmetirom require regular LDL monitoring because the drug reduces LDL cholesterol as part of its mechanism of action — a clinically relevant pharmacodynamic effect that requires surveillance and potential statin dose adjustment. Platforms that track resmetirom adherence, LDL trends, and concomitant lipid-lowering therapy must remain available at every lipid management encounter to prevent both under-monitoring and inappropriate statin adjustments.
Metabolic risk factor tracking drives the multi-organ management required in MASLD. MASLD is a systemic metabolic disease requiring coordinated management of body weight, glucose, blood pressure, and lipids alongside liver-specific interventions. Platforms that aggregate metabolic panel trends, A1C trajectories, weight loss progress, and medication adherence data support the multi-disciplinary care model that achieves best clinical outcomes. Platform unavailability that fragments this longitudinal view forces clinicians to manage individual risk factors in isolation rather than as components of an integrated metabolic phenotype.
Progression surveillance scheduling failures delay cirrhosis detection. For patients with bridging fibrosis (F3) or compensated cirrhosis (F4), surveillance scheduling for hepatocellular carcinoma screening (ultrasound and AFP every 6 months) and endoscopy for varices is a patient safety imperative. Platforms that manage surveillance scheduling and send automated reminders prevent the surveillance gaps that allow preventable complications to develop undetected. When scheduling and reminder systems fail, patients miss time-sensitive screening windows.
Silent EHR integration failures fragment care across the metabolic medicine team. NAFLD/NASH patients are frequently co-managed by primary care, endocrinology, cardiology, and hepatology. Platform integration failures that prevent liver disease data from reaching the primary care EHR silently fragment the multi-disciplinary record — and the fragmentation is often discovered only when a care coordinator notices that the hepatology data is missing from the integrated chart.
What to Monitor on a NAFLD/NASH Care Tech Platform
Imaging Results and FibroScan Repository API
The imaging and non-invasive assessment result storage and retrieval service is the highest-priority monitoring target. Check at a 1-minute interval with immediate escalation. Inaccessible FibroScan liver stiffness data or MRI-PDFF results during a staging encounter makes treatment initiation decisions clinically unjustifiable.
Resmetirom Adherence and LDL Monitoring Service
Monitor the pharmacotherapy adherence tracking and LDL trending API at a 1-minute interval. For patients on resmetirom, unmonitored LDL drift carries cardiovascular risk. Adherence data failures prevent the dose-response assessment that guides ongoing therapy.
Metabolic Risk Factor Dashboard
Monitor the metabolic panel aggregation and trending service — covering weight, glucose/A1C, blood pressure, and lipid trajectories — at a 2-minute interval. This service drives the integrated risk factor management that distinguishes effective MASLD programs from fragmented single-organ management.
Progression Surveillance Scheduling API
Monitor the surveillance scheduling and reminder service at a 2-minute interval. For F3/F4 patients, surveillance scheduling failures translate directly to missed hepatocellular carcinoma screening and variceal surveillance windows.
Non-Invasive Biomarker Trending Service
Monitor the biomarker aggregation service — covering ELF score, FIB-4, liver stiffness serial measurements, and enhanced liver fibrosis biomarker panels — at a 2-minute interval. These biomarkers form the non-invasive progression surveillance backbone that has replaced serial biopsy for most MASLD patients.
Patient-Facing App and Lifestyle Tracking Integration
Monitor the patient-facing weight management, dietary logging, and physical activity tracking API at a 2-minute interval. Lifestyle modification remains the cornerstone of MASLD management. Patient engagement platform failures break the behavioral data stream that clinicians use to assess lifestyle intervention effectiveness.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. MASLD is managed across multiple specialties; silent EHR integration failures create the fragmented records that undermine multi-disciplinary care coordination.
Referral and Care Coordination API
Monitor the hepatology referral routing and care coordination service at a 5-minute interval. Timely escalation of patients with significant fibrosis to hepatology depends on intact referral routing.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock every clinician and patient simultaneously out of the platform's longitudinal data — staging records, adherence histories, metabolic trajectories, and surveillance schedules — at once.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance on all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for NAFLD/NASH Care Tech Platforms
Immediate clinical escalation: Imaging results API, resmetirom adherence and LDL monitoring service, authentication service. Failures here affect active staging and pharmacotherapy management encounters.
Immediate clinical operations escalation: Metabolic risk factor dashboard, progression surveillance scheduling, non-invasive biomarker trending service. These affect the longitudinal disease management workflow.
Business-hours engineering escalation: EHR synchronization, referral routing, patient-facing app integration. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all platform domains.
MASLD programs serving geographically distributed patients — particularly rural or underserved populations where FibroScan access requires travel to regional centers — benefit from multi-region monitoring. A regional outage that blocks access to imaging results on a day when a patient has traveled for a FibroScan assessment wastes a time-sensitive clinical encounter.
Status Page as a Clinical Operations Trust Signal
Hepatology and metabolic medicine clinic operations depend on predictable platform availability. A published status page allows clinic schedulers and front-desk staff to distinguish between a local connectivity issue and a platform incident — enabling rapid decisions about whether to postpone a staging encounter that would be clinically incomplete without imaging data access, or to implement a phone-based clinical workflow when the patient-facing app is degraded.
For multi-disciplinary MASLD programs with hepatology, endocrinology, and primary care participating in shared care plans, a status page reduces the cross-specialty confusion that occurs when one team's workflow appears broken while others' continues normally. Publish the status page URL in clinic supervisor workstations, multi-disciplinary team communication channels, and the clinical operations escalation runbook.
The Business Case: Pharmacotherapy Oversight, Payer Authorization, and Program Growth
Resmetirom is a high-cost specialty medication. Payer authorizations for resmetirom require documented FibroScan or MRI-based fibrosis staging, metabolic comorbidity profiles, and adherence monitoring plans. Platforms that generate and maintain this documentation create a billing and authorization asset; outages that create documentation gaps generate prior authorization denials and appeals workloads that consume clinical staff time and delay treatment initiation.
Longitudinal MASLD programs are among the fastest-growing specialty service lines in gastroenterology and hepatology, driven by resmetirom approval and growing recognition of MASLD as a systemic metabolic disease. Programs that demonstrate consistent platform reliability attract multi-disciplinary referral relationships from primary care and endocrinology partners who need to trust that their referred patients will be well-managed. Programs with repeated platform failures erode referral confidence.
For academic medical centers and health systems building MASLD center-of-excellence designations, platform availability documentation is an operational quality metric. External monitoring from Vigilmon provides the independent availability record that program directors can present to health system leadership, payer value-based care teams, and specialty society accreditation programs.
Vigilmon Setup for NAFLD/NASH Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Imaging results and FibroScan API | 1 min | PagerDuty + clinical ops (immediate) | | Resmetirom adherence and LDL service | 1 min | PagerDuty (immediate) | | Auth service | 1 min | PagerDuty (immediate) | | Metabolic risk factor dashboard | 2 min | PagerDuty + Slack (immediate) | | Progression surveillance scheduling | 2 min | PagerDuty (immediate) | | Non-invasive biomarker trending | 2 min | PagerDuty (immediate) | | Patient-facing app integration | 2 min | Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | Referral routing API | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the imaging results and FibroScan API at a 1-minute interval with immediate clinical ops escalation
- Add the resmetirom adherence and LDL monitoring service with immediate PagerDuty alerting
- Add authentication at a 1-minute interval
- Add the metabolic risk factor dashboard and progression surveillance scheduling at 2-minute intervals
- Add non-invasive biomarker trending and patient-facing app monitoring
- Add EHR synchronization and referral routing with business-hours escalation
- Enable SSL monitoring across all platform domains
- Publish the automatic status page URL in clinic supervisor workstations, multi-disciplinary team channels, and operations runbooks
Conclusion
NAFLD/NASH care technology platforms are the longitudinal data engines of metabolic liver disease programs — holding the FibroScan trajectories, MRI-PDFF histories, resmetirom adherence records, metabolic risk factor trends, and surveillance schedules that define each patient's position on the fibrosis progression curve and guide every treatment decision. When these platforms are unavailable, clinicians are navigating a complex, data-dependent specialty without the data. Staging decisions become guesswork, resmetirom oversight becomes incomplete, and surveillance windows that should trigger hepatocellular carcinoma screening are silently missed.
External monitoring from Vigilmon provides the independent, outside-in availability view that MASLD program directors and health IT teams need to detect failures before they affect clinical encounters — with the documented incident record that payers, health system administrators, and accreditation bodies require as evidence of the operational maturity that specialty liver disease programs demand.
Start monitoring your NAFLD/NASH care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #NAFLD #NASH #MASLD #healthtech #liverhealth #resmetirom #FibroScan #metabolicsyndrome #uptime #hepatology #compliance #sre